Published in J Med Chem on January 21, 1994
Large-scale synthesis of all stereoisomers of a 2,3-unsaturated C-glycoside scaffold. J Org Chem (2011) 0.84
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology (1989) 5.24
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 3.58
Justice at the millennium: a meta-analytic review of 25 years of organizational justice research. J Appl Psychol (2001) 3.16
Stability of protein pharmaceuticals. Pharm Res (1989) 2.92
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 2.72
An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A (1990) 2.32
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol (2001) 1.63
The integrated value of serum procollagen III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat. Hepatology (1989) 1.60
Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells. J Biol Chem (1984) 1.54
Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother (1997) 1.53
Are graduate programs training pharmaceutical scientists to function effectively in the new, highly integrated and globalized pharmaceutical industry? Pharm Res (1997) 1.52
L-Dopa-induced release of cerebral monoamines. Science (1970) 1.47
Identification of Arcobacter cryaerophilus isolated from a traffic accident victim with bacteremia by 16S ribosomal RNA gene sequencing. Diagn Microbiol Infect Dis (2001) 1.47
Sinefungin, a potent inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral multiplication. J Biol Chem (1978) 1.47
Structure determination of selenomethionyl S-adenosylhomocysteine hydrolase using data at a single wavelength. Nat Struct Biol (1998) 1.42
Studies of inhibition of rat spermidine synthase and spermine synthase. Biochem J (1980) 1.38
Beta-lactam resistance in Staphylococcus aureus: the adaptive resistance of a plastic genome. Cell Mol Life Sci (2005) 1.38
Infection due to the fungus Acremonium (cephalosporium). Medicine (Baltimore) (1991) 1.35
Proteases from human immunodeficiency virus and avian myeloblastosis virus show distinct specificities in hydrolysis of multidomain protein substrates. J Virol (1990) 1.33
Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide. Pharm Res (1990) 1.32
Transport of a large neutral amino acid (phenylalanine) in a human intestinal epithelial cell line: Caco-2. Biochim Biophys Acta (1990) 1.31
S-adenosyl-L-homocysteine hydrolase as a target for antiviral chemotherapy. J Med Chem (1991) 1.30
Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet (1998) 1.30
Structure and function of S-adenosylhomocysteine hydrolase. Cell Biochem Biophys (2000) 1.29
Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem (1990) 1.29
Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem (1998) 1.29
Molecular epidemiology of Vibrio cholerae in Hong Kong. J Clin Microbiol (1989) 1.29
Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease. Biochemistry (1990) 1.26
S-Adenosyl-L-methionine-dependent macromolecule methyltransferases: potential targets for the design of chemotherapeutic agents. J Med Chem (1980) 1.25
Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem (1996) 1.24
Chemical pathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides. Pharm Res (1990) 1.24
Paracellular diffusion in Caco-2 cell monolayers: effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. J Pharm Sci (1997) 1.22
Clonidine delays small intestinal transit in the rat. J Pharmacol Exp Ther (1980) 1.22
Effects of inhibitors of spermidine and spermine synthesis on polyamine concentrations and growth of transformed mouse fibroblasts. Biochem J (1981) 1.20
How structural features influence the biomembrane permeability of peptides. J Pharm Sci (1996) 1.19
Urinary tract infections due to Candida albicans. Rev Infect Dis (1983) 1.19
Subcutaneous phaeohyphomycotic abscess caused by Phialophora parasitica in a renal allograft recipient. J Med Vet Mycol (1988) 1.17
Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus. J Biol Chem (1991) 1.16
Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem (2000) 1.16
Effects of adenosine dialdehyde on S-adenosylhomocysteine hydrolase and S-adenosylmethionine-dependent transmethylations in mouse L929 cells. Mol Pharmacol (1984) 1.15
Therapeutic failures with miconazole. Antimicrob Agents Chemother (1978) 1.14
Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria. Infect Immun (1987) 1.13
Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier. Ann N Y Acad Sci (1987) 1.13
Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling. Protein Sci (1992) 1.13
Carbachol stimulation of gastrointestinal transit in the postoperative lleus rat. J Surg Res (1979) 1.11
A convenient preparation of S-adenosylhomocysteine and related compounds. J Org Chem (1976) 1.09
Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem (1994) 1.09
Purification and characterization of heterodimeric human immunodeficiency virus type 1 (HIV-1) reverse transcriptase produced by in vitro processing of p66 with recombinant HIV-1 protease. J Biol Chem (1992) 1.08
Effects of S-adenosylhomocysteine analogues on vaccinia viral messenger ribonucleic acid synthesis and methylation. Biochemistry (1982) 1.08
Transport of bile acids in a human intestinal epithelial cell line, Caco-2. Biochim Biophys Acta (1990) 1.07
Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm Res (1994) 1.07
The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharm Res (1990) 1.06
Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives. Antimicrob Agents Chemother (1989) 1.06
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones. J Med Chem (1997) 1.06
Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther (1999) 1.05
In vitro systems for studying intestinal drug absorption. Med Res Rev (1995) 1.05
Near-drowning complicated by brain abscess due to Petriellidium boydii. Arch Neurol (1982) 1.05
Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 6. Structural modifications of S-adenosylmethionine. J Med Chem (1976) 1.05
Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng (1995) 1.04
Evidence for noncholinergic mediation of small intestinal transit in the rat. J Pharmacol Exp Ther (1979) 1.04
Rational approaches to the design of antiviral agents based on S-adenosyl-L-homocysteine hydrolase as a molecular target. Antiviral Res (1992) 1.04
Chiral instability at sulfur of S-adenosylmethionine. Biochemistry (1983) 1.04
Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm Res (1997) 1.03
Characterization of the unstirred water layer in Caco-2 cell monolayers using a novel diffusion apparatus. Pharm Res (1991) 1.03
Interdomain hydrolysis of a truncated Pseudomonas exotoxin by the human immunodeficiency virus-1 protease. J Biol Chem (1990) 1.03
Stereopopulation control. II. Rate enhancement of intramolecular nucleophilic displacement. J Am Chem Soc (1972) 1.02
9-(trans-2',trans-3'-Dihydroxycyclopent-4'-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity. Antimicrob Agents Chemother (1987) 1.02
Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J Pharm Sci (1997) 1.01
Amine prodrugs which utilize hydroxy amide lactonization. II. A potential esterase-sensitive amide prodrug. Pharm Res (1991) 1.01
Interferon as a defence mechanism in mouse cytomegalovirus infection. J Gen Virol (1983) 1.01
The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. J Biol Chem (1993) 1.01
Metal affinity chromatography of recombinant HIV-1 reverse transcriptase containing a human renin cleavable metal binding domain. Biotechnol Appl Biochem (1991) 0.99
Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. Biochemistry (1995) 0.99
Murine cytomegalovirus particle types in relation to sources of virus and pathogenicity. J Gen Virol (1981) 0.99
Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Pharm Res (1997) 0.98
Penetration of amphotericin B into the human eye. J Infect Dis (1983) 0.98
Sinefungin, a potent inhibitor or S-adenosylmethionine: protein O-methyltransferase. Biochem Biophys Res Commun (1979) 0.97
The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res (1996) 0.97
Inhibition of Newcastle disease virion messenger RNA (guanine-7-)-methyltransferase by analogues of S-adenosylhomocysteine. Biochemistry (1977) 0.97
Protective effects of 16,16-dimethyl PGE2 on the liver and kidney. Prostaglandins (1981) 0.97
Tissue penetration of clindamycin in diabetic foot infections. J Antimicrob Chemother (1993) 0.97
Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm Res (1993) 0.97
Bioassay for miconazole. Antimicrob Agents Chemother (1977) 0.96
Hexose uptake in primary cultures of bovine brain microvessel endothelial cells. I. Basic characteristics and effects of D-glucose and insulin. Biochim Biophys Acta (1991) 0.96
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1. Biochemistry (1991) 0.96
Naloxone inhibits the anti-diarrhoeal activity of loperamide. Br J Pharmacol (1979) 0.95
Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli. Antimicrob Agents Chemother (1981) 0.95
Effect of oestrogen and 1,25-dihydroxycholecalciferol on 25-hydroxycholecalciferol metabolism in primary chick kidney-cell cultures. Biochem J (1978) 0.95
Characterization of an in vitro blood-brain barrier model system for studying drug transport and metabolism. Pharm Res (1986) 0.95